Evidence map›Paper›PMID 42058230›Full record

ReviewJournal of pharmaceutical policy and practice2026

Developing a framework to assess off-patent medicines policies in Latin America and the Caribbean.

Jaime Espín, Santiago Palacio-Ciro, Ana Amaris, Pamela Gongora-Salazar, Veronika J Wirtz

Abstract readReview
In one paragraph

Review in Journal of pharmaceutical policy and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jaime EspínAndalusian School of Public Health, Escuela Andaluza de Salud Pública (EASP), Granada, Spain.ORCID https://orcid.org/0000-0001-7299-6554
Santiago Palacio-CiroCentre for Health Economics, University of York, York, UK.ORCID https://orcid.org/0000-0002-7129-7425
Ana AmarisConsultant, Washington DC, USA.ORCID https://orcid.org/0000-0002-1590-8412
Pamela Gongora-SalazarHealth, Nutrition and Population Division, Inter-American Development Bank, Washington, DC, USA.ORCID https://orcid.org/0000-0002-3160-7097
Veronika J WirtzDepartment of Global Health, Boston University School of Public Health, Boston, MA, USA.ORCID https://orcid.org/0000-0002-0863-8768

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Countries in Latin America and the Caribbean (LAC) often lack a systematic approach to assessing the maturity and effectiveness of their policies for promoting off-patent (generic and biosimilar) medicines. Currently, no comprehensive, region-specific methodology exists that encompasses both generics and biosimilars. The objective of this paper is to develop a framework for assessing the performance of off-patent medicines policies that LAC countries can use to identify opportunities to improve access to these medicines in their territories. Methods: Through a scoping review of over 300 studies, this study identifies key supply- and demand-side policy interventions to promote generics and biosimilars, along with corresponding outcome indicators. This informs a logic-model-based framework, where supply-side policies are organized according to the pharmaceutical value chain, and demand-side policies are based on the target population. Results: The framework maps key policy actions, such as regulation, pricing, and substitution, to expected outcomes, such as affordability, uptake, and trust. The review highlights major regional gaps, including insufficient biosimilar policies, limited empirical evaluations, and the unique duality between public and private healthcare sectors in LAC. The existing literature gives greater attention to demand-side policies as potential factors driving higher market participation in generic and biosimilar medicines. Within this component, the emphasis is on factors aimed at education and awareness initiatives for users (41.6%). Supply-side policies are discussed less frequently, with price regulation (28.9%) most cited. By contrast, limited attention is given to other key factors such as horizon scanning, and mark-up regulation. Conclusion: The proposed framework serves as a diagnostic, analytical, and benchmarking instrument for policymakers and academia. It facilitates structured assessment, supports policy design, and fosters regional learning. Piloting and further empirical research are recommended to refine and validate the framework using a specific tool designed for this purpose.

Indexed as

BiosimilarsGenericsLatin America and the CaribbeanOff-patent medicinesPharmaceutical policiesScoping review

Identifiers

PMID42058230
PMCPMC13123092

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.